Kite Pharma (KITE): Topline Data From PII ZUMA-1 Shows Approvability - Jefferies

September 27, 2016 7:09 AM EDT
Get Alerts KITE Hot Sheet
Price: $47.58 +0.25%

Rating Summary:
    16 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade KITE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after the company reported topline data from the PII ZUMA-1 study in NHL. The 3-month interim analysis reported an ORR/CR of 79%/52% with a 3-month rate of 44%/39%. In DLBCL, KITE reported an ORR/CR of 76%/47% that moderated to 39%/33% at 3 months. the analyst views the 3-month CR rate across the entire ZUMA-1 cohort as favorable and suggestive of a durable response.

These results support the approvability of KTE-C19 and there are likely to be more details at KITE's investor day (10/18/16) as well as more information around the commercial aspects of KTE-C19 and ASH in December. An FDA mtg is planned in the next few months that could lead to a BLA filing in DLBCL, TFL, and PMBCL by YE2016.

No change to the price target of $72.

For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.

Shares of Kite Pharma closed at $54.98 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment